简要报告:从IPSOS第三阶段研究中对NSCLC中白金不合格的后期验证
Solange Peters1, Christian Schulz2, Martin Reck3
1Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.
概括
阿特佐利祖马布改善了非小细胞肺癌 (NSCLC) 患者的生存率和生活质量,这些患者不符合化疗的条件. 这项研究改进了选择患者接受阿特佐利祖马布治疗的标准.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 免疫治疗是一种免疫疗法.
背景情况:
- 第三阶段IPSOS研究表明,阿特佐利祖马布在不符合化疗资格的NSCLC患者中的疗效.
- 对于在NSCLC中定义不合格的定义,没有达成共识.
- 进行了后期分析,以评估精炼不合格 (sPI) 人群的结果.
研究的目的:
- 通过使用精确的标准,在选定的不合格 (sPI) 人群中评估临床结果.
- 评估阿特佐利祖马布的疗效和安全性与单剂化疗在这个特定的NSCLC亚组.
主要方法:
- 患有IIIB/IV期不符合双化学疗法的NSCLC患者被随机分配给阿特佐利祖马布或化疗.
- 该sPI亚组包括患有3个ECOGPS的患者,年龄大于80岁,ECOGPS2并发症,或70岁以上并发症的患者.
- 在453名患者中,有405名 (89%) 符合sPI标准.
主要成果:
- 与化疗相比,阿特佐利祖马布改善了整体存活率 (HR 0.78).
- 较少的3/4级与治疗相关的不良事件被观察到与阿特佐利祖马布 (17.3%对34.3%).
- 阿特佐利祖马布稳定或改善了患者报告的与健康有关的生活质量.
结论:
- 第一线阿特佐利祖马布在sPI群体中提供长期生存和有利的安全概况.
- 精确的sPI标准可以帮助临床决策对NSCLC治疗选择.
- 结果与IPSOS试验的整体结果一致.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...